The researchers hope that the protein they investigated, which experts call amyloid-beta-binding anticalin (H1GA), can halt the progression of the severe neurodegenerative disease at an early stage.

This time last year, Pieris also lost a partnership with AstraZeneca on respiratory drug candidate elarekibep, one of up to five Anticalin therapies covered by a deal also signed in 2017 ...